Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abiraterone acetate - Churchill Pharmaceuticals

Drug Profile

Abiraterone acetate - Churchill Pharmaceuticals

Alternative Names: AAFP; Abiraterone acetate fine particle ; submicron abiraterone acetate; Yonsa

Latest Information Update: 27 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Churchill Pharmaceuticals
  • Class Androstenols; Antiandrogens; Antineoplastics; Phenanthrenes; Pyridines; Small molecules
  • Mechanism of Action CYP17A1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Prostate cancer

Most Recent Events

  • 07 Jul 2020 Institute of Cancer Research in United Kingdom plans the phase I/II ACTIon trial in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in Switzerland and United Kingdom (NCT04458311)
  • 08 Jun 2018 Chemical structure information added
  • 23 May 2018 Abiraterone acetate licensed to Sun Pharma in USA
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top